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Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the charac-
teristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, includ-
ing huge splenomegaly, higher cell count and higher blast cell percentage.
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Patients and methods: To investigate if after childhood the disease maintains or loses these characteristics of aggres-
siveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMACMLWP over a 40-year period.
Results: Young adults (YAs: 18–29 years old) significantly differed from adults (30–59 years old) and elderly patients (at
least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen
size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk
patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine
kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs,
and the probability of transformation was higher (16%, 5% and 7%, P = 0.011).
Conclusions: The characteristics of CML or the host response to leukemia differ with age. The knowledge of these
differences and of their causes may help to refine the treatment and to improve the outcome.
Clinical trial numbers: NCT00510926, NCT00514488, NCT00769327, NCT00481052.
Key words: chronic myeloid leukemia, BCR-ABL, prognosis, young adults, tyrosine kinase inhibitors
introduction
Chronic myeloid leukemia (CML) is characterized by a specific
genomic abnormality, the BCR-ABL1 gene, coding for a tyro-
sine kinase protein (PTK) and causing the leukemic transform-
ation of hemopoietic stem cells [1]. In absence of treatment, the
outcome is fatal and the course varies from few months to many
years. Also with very effective treatments, as tyrosine kinase
inhibitors (TKIs), about 20% of patients are still at risk of dying
of leukemia [1–5]. The prognosis of CML is still based on three
scoring systems including clinical and hematologic variables,
such as spleen size, platelet count, and the percentage of blast
cells, eosinophils and basophils in the peripheral blood. The
Sokal [6] and EURO [7] scoring systems, based on the overall
survival (OS) of CML patients treated with conventional chemo-
therapy and with recombinant interferon-α (rIFN-α), respect-
ively, also include the age: some patients are classified in the
high Sokal and EURO risk category mainly because of old age,
and some patients are not classified in the high Sokal and
Table 1. Baseline demographic and hematologic characteristics, according to the frontline treatment
CHT rIFN-α TKIs Total
Patient number, N (%) 948 (34) 1062 (38) 774 (28) 2784
Gender male, N (%) 510 (54) 630 (59) 450 (58) 1590 (57)
Age, years, median (range) 52 (18–87) 46 (18–74) 52 (18–86) 50 (18–87)
Spleen, cma, median (range) 4.0 (0–30.0) 3.5 (0–25.0) 1 (0–24.0) 3 (0–30.0)
Palpable spleen, N (%) 601 (63) 687 (65) 436 (56) 1724 (62)
Blastsb, %, median (range) 1.0 (0–14.5) 1.0 (0–12.0) 1.0 (0–10.0) 1.0 (0–14.5)
Basophilsb, %, median (range) 2.0 (0–19.5) 2.0 (0–19.5) 2.0 (0–19.0) 2.0 (0–19.5)
Eosinophilsb, %, median (range) 1.0 (0–37.0) 2.0 (0–24.0) 2.0 (0–19.0) 2.0 (0–37.0)
PLT count, 103/ml; median (range) 350 (100–3412) 355 (100–3018) 353 (101–4920) 352 (100–4920)
Hemoglobin, g/dl, median (range) 12.0 (4.0–17.8) 12.0 (5.3–18.4) 12.4 (6.4–17.5) 12.1 (4.0–18.4)
WBC count, 103/ml; median (range) 94 (14–880) 52 (13–780) 47 (12–544) 58 (12–880)
Sokal score, N (%)
Low 328 (35) 489 (46) 301 (39) 1118 (40)
Intermediate 350 (37) 352 (33) 310 (40) 1012 (36)
High 270 (28) 216 (20) 163 (21) 649 (23)
NE 0 5 (1) 0 5 (1)
EURO score, N (%)
Low 354 (37) 539 (51) 327 (42) 1220 (44)
Intermediate 441 (47) 422 (40) 398 (51) 1261 (45)
High 110 (12) 91 (9) 49 (6) 250 (9)
NE 43 (5) 10 (1) 0 53 (2)
EUTOS score, N (%)
Low 807 (85) 938 (88) 725 (94) 2470 (89)
High 98 (10) 114 (11) 49 (6) 261 (9)
NE 43 (5) 10 (1) 0 53 (2)
aMaximum distance below the costal margin, assessed by manual palpation.
bPercentage in peripheral blood.
CHT, chemotherapy; rIFN-α, recombinant interferon-α; TKIs, tyrosine kinase inhibitors; PLT, platelets; WBC, white blood cells; NE, not evaluable.
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EURO risk category mainly because of young age. The more
recent EUTOS scoring system, designed to predict the complete
cytogenetic response (CCyR) probability at 18 months in TKIs-
treated CML patients, did not account for age [8, 9]. It is known
since many years that, in children Ph+, BCR-ABL-positive,
CML have more aggressive clinical and hematologic features,
particularly huge splenomegaly, high white blood cell (WBC)
count and higher blast cell percentage [10–13]. It is unclear if
and how much these characteristics of aggressiveness are still
present after childhood and, if so, how long. For this purpose,
we reviewed all the GIMEMA CML databases, spanning over 40
years, to investigate if in adults the characteristics of the disease
and the risk score distribution differ according to the age.
methods
The GIMEMA CML Working Party, previously Italian Cooperative Study
Group on CML, promoted several multicentric prospective clinical studies
since 1972 to today. A total number of 2784 adult, ≥18 years old, chronic
phase (CP) CML patients were enrolled: 948 (34%) treated frontline with
chemotherapy between 1972 and 1988, 1062 (38%) treated frontline with
rIFN-α-based regimes between 1986 and 2002, 774 (28%) treated frontline
with TKIs, mainly imatinib and nilotinib, between 2003 and 2010. An allo-
geneic stem-cell transplantation (alloSCT) was carried out in 83/948 patients
(9%) in the chemotherapy cohort, in 292/1062 patients (27%) in the rIFN-α
cohort, and in 22/774 patients (3%) in the TKIs cohort, respectively.
The diagnosis of CML was based on the identification of the Ph chromo-
some by chromosome banding analysis of marrow cell metaphases, or on
interphase fluorescence in situ hybridization in case of masked Ph, and after
2001 also on the demonstration of the BCR-ABL transcript by polymerase
chain reaction, as recommended [5]. The European LeukemiaNet (ELN) cri-
teria for distinguishing CP from accelerated and blastic phase (AP and BP)
were used [4, 5]. The hematologic, cytogenetic and molecular responses were
defined as recently recommended by ELN [5]. Baseline data were obtained
before any treatment. The spleen size was always reported as maximum dis-
tance in centimeters below the costal margin, as assessed by manual palpa-
tion. Risk scores were calculated according to the original reports [6–8]. All
patients provided written informed consent before the enrollment. All
studies were approved by the Institutional Review Board of all participating
institutions and carried out in accordance with the Declaration of Helsinki,
but only the most recent studies could be preregistered at NCT.
Baseline characteristics and hematological data were compared by the χ2
or the Kruskal–Wallis tests, as appropriate. The survival times were calcu-
lated from the date of treatment start until death for any cause (OS) or leuke-
mia-related death (leukemia-related survival). The death was attributed to
leukemia in all the patients who died after progression to AP or BP or with
hematologic evidence of leukemia, who died after alloSCT, or who died due
to unknown reasons. The cumulative incidence of progression was calculated
from the date of start of treatment until the date of transformation to AP or
BP. The patients who underwent alloSCT were not censored at transplant.
Table 2. Baseline demographic and hematologic characteristics, according to age, at diagnosis
<30 years 30–39 years 40–49 years 50–59 years 60–69 years ≥70 years
Patient number, N (%) 329 (12) 444 (16) 613 (21) 693 (25) 473 (17) 232 (8)
Gender male, N (%) 201 (61) 279 (63) 335 (55) 401 (58) 260 (55) 114 (49)
Spleen, cma, median (range) 4.5 (0–28.0) 5.0 (0–27.0) 3.0 (0–25.0) 2.0 (0–28.0) 1.8 (0–30.0) 1.0 (0–20.0)
Palpable spleen, N (%) 234 (71) 312 (70) 379 (62) 414 (60) 266 (56) 119 (51)
Blastsb, %, median (range) 1.0 (0–14.5) 1.0 (0–12.0) 1.0 (0–10.0) 1.0 (0–14.0) 1.0 (0–14.5) 0.7 (0–14.0)
Basophilsb, %, median (range) 2.0 (0–19.5) 2.0 (0–19.0) 2.0 (0–19.5) 2.0 (0–19.5) 2.0 (0–16.0) 2.0 (0–16.0)
Eosinophilsb, %, median (range) 2.0 (0–16.0) 2.0 (0–10.0) 2.0 (0–23.0) 2.0 (0–37.0) 1.3 (0–12.0) 2.0 (0–11.0)
PLT count, 103/ml; median (range) 370 (100–3018) 355 (100–4920) 380 (100–4553) 350 (100–3594) 333 (100–1750) 345 (100–2208)
Hemoglobin, g/dl, median (range) 11.8 (6.0–17.0) 12.1 (5.3–16.7) 12.0 (4.0–17.8) 12.2 (5.6–18.4) 12.3 (4.5–17.0) 12.1 (5.3–16.2)
WBC count, 103/ml; median (range) 62 (15–880) 66 (16–516) 54 (14–780) 57 (13–600) 54 (12–544) 71 (12–481)
Sokal score, N (%)
Low 199 (60) 243 (55) 302 (49) 258 (37) 115 (24) 1 (1)
Intermediate 64 (19) 134 (30) 182 (30) 259 (37) 225 (48) 148 (64)
High 66 (20) 67 (15) 127 (21) 173 (25) 133 (28) 83 (36)
NE 0 0 2 (1) 3 (1) 0 0
EURO score, N (%)
Low 228 (69) 325 (73) 457 (75) 99 (14) 79 (17) 32 (14)
Intermediate 82 (25) 99 (22) 125 (20) 453 (65) 332 (70) 170 (73)
High 15 (5) 7 (2) 14 (2) 131 (19) 54 (11) 29 (12)
NE 4 (1) 13 (3) 17 (3) 10 (1) 8 (2) 1 (1)
EUTOS score, N (%)
Low 267 (81) 392 (88) 539 (88) 615 (89) 438 (93) 219 (94)
High 58 (18) 39 (9) 57 (9) 68 (10) 27 (6) 12 (5)
NE 4 (1) 13 (3) 17 (3) 10 (1) 8 (2) 1 (1)
aMaximum distance below the costal margin, assessed by manual palpation.
bPercentage in peripheral blood.
PLT, platelets; WBC, white blood cells; NE, not evaluable.
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The survival probabilities and the cumulative incidences were estimated
using the Kaplan–Meier method. Survival times and times to event were
compared by the log-rank test.
results
baseline characteristics
The baseline demographic and hematologic characteristics are
shown in Table 1. The frequency of high-risk patients decreased
over the years: from 28% to 21% by Sokal score; from 12% to 6%
by EURO score and from 10% to 6% by EUTOS score.
The patient characteristics according to the age are shown
in Table 2. Only the spleen size showed an impressive variabil-
ity, ranging from a median value of 4.5 cm in the youngest
group (18–29 years old) to a median value of 1.0 cm in the
oldest one (≥70 years old), with a progressive decrease, start-
ing at the age of 40. As expected, the proportion of high Sokal
and high EURO score patients increased with age, rising from
20% and 5%, respectively, in the youngest patients, to 36% and
12%, respectively, in the oldest patients. Conversely, the pro-
portion of high EUTOS score patients was highest (18%) in
the youngest age group (18–29 years), intermediate (9–10%)
in patients 30–59 years old, and lowest (5–6%) in patients ≥60
years old. Based on the EUTOS score distribution, in all subse-
quent calculations, the patients were divided into three age
groups, 18–29 years old, 30–59 years old and ≥60 years old;
high-risk patients, were 18%, 9% and 6%, respectively,
P < 0.001. An analysis of baseline characteristics within the
three age groups has been carried out (Table 3 and supple-
mentary Table S1, available at Annals of Oncology online).
The main difference among the three age groups was the pro-
portion of patients with a palpable spleen (71%, 63% and 55%,
respectively, P < 0.001) and the spleen size (median, 4.5, 3.0
and 1.0 cm below costal margin respectively, P < 0.001).
Moreover, the patients <30 years old were more frequently
males, had a higher blast cell percentage in the peripheral
blood, a lower hemoglobin concentration and a slightly higher
platelet count (Table 3).
Table 3. Comparison of baseline demographic and hematologic characteristics among young adults, adults and elderly (18–29 years, 30–59 years,
≥60 years)
<30 years years ≥60 years P
Patient number, N (%) 329 (12) 1750 (63) 705 (25) -
Gender male, N (%) 201 (61) 1015 (58) 374 (53) 0.024
Spleen, cma, median (range) 4.5 (0–28.0) 3.0 (0–28.0) 1.0 (0–30.0) <0.001
Palpable spleen, N (%) 234 (71) 1105 (63) 385 (55) <0.001
Blastsb, %, median (range) 1.0 (0–14.5) 1.0 (0–14.0) 1.0 (0–14.5) 0.003
Basophilsb, %, median (range) 2.0 (0–19.5) 2.0 (0–19.5) 2.0 (0–16.0) 0.485
Eosinophilsb, %, median (range) 2.0 (0–16.0) 2.0 (0–37.0) 2.0 (0–12.0) 0.410
PLT count, 103/ml, median (range) 370 (100–3018) 358 (100–4920) 336 (102–2208) 0.041
Hemoglobin, g/dl, median (range) 11.8 (6.0–17.0) 12.1 (4.0–18.4) 12.2 (4.5–17.0) 0.019
WBC count, 103/ml, median (range) 61 (15–880) 57 (13–780) 59 (12–544) 0.627
e13a2 transcript presentc, N (%)d 30 (54) 202 (44) 122 (47) 0.382
CCA Ph+, N (%)d 2 (4) 22 (5) 8 (3) 0.514
Variant translocation, N (%)d 0 27 (6) 21 (8) 0.071
Sokal score, N (%)
Low 199 (60) 803 (46) 116 (16) <0.001
Intermediate 64 (19) 575 (33) 373 (53)
High 66 (20) 367 (21) 216 (31)
NE 0 5 (1) 0
EURO score, N (%)
Low 228 (69) 881 (50) 111 (16) <0.001
Intermediate 82 (25) 677 (39) 502 (71)
High 15 (5) 152 (9) 83 (12)
NE 4 (1) 40 (2) 9 (1)
EUTOS score, N (%)
Low 267 (81) 1546 (88) 657 (93) <0.001
High 58 (18) 164 (9) 39 (6)
NE 4 (1) 40 (2) 9 (1)
aMaximum distance below the costal margin, assessed by manual palpation.
bPercentage in peripheral blood.
cPatients with e13a2 transcript or with both e13a2/e14a2 transcripts were included.
dAvailable data in 774 patients: age <30 years, 56 patients; age 30–59 years, 457 patients; age >60 years, 261 patients.
PLT, platelets; WBC, white blood cells; e13 a2 transcript, b2a2 BCR-ABL transcript; CCA Ph+, clonal chromosomal abnormalities in Philadelphia
positive cells; NE, not evaluable.
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response to therapy and outcome
The response to the therapy was fully evaluable only in the TKIs
cohort. In this cohort, the cumulative incidence of CCyR by 5
years was lower in the young adult (YA) group (80%) than in
the remaining two age groups (90% in both groups) (P = 0.041,
YA compared with all others). Also the cumulative incidence of
major molecular response (MMR) by 5 years was lower in the
YA group (71%) than in the two other age groups (86% and
88%) (P = 0.004, YA compared with all others).
The OS according to the frontline treatment and by age group
is shown in Figure 1. In the chemotherapy and in the rIFN-α
cohorts, the OS was better in YA than in adult patients, and it
was better in adult than in elderly patients. In the TKIs cohort,
the difference between YA and adults disappeared, and both
groups had higher OS than the elderly group (P < 0.001). In the
chemotherapy and in the rIFN-α cohorts, the leukemia-related
deaths were 97% and 96%, respectively. In the TKIs cohort, all
deaths in the YA group were leukemia-related, while the leuke-
mia-related deaths occurring in the adult and elderly groups
were 69% and 40%, respectively (Table 4). The 5-year estimated
probability of progression to AP and BP was 16% in the YA
group, 5% in the adult group and 7% in the elderly group
(P = 0.011) (Figure 2). Therefore, the leukemia-related survival
was much less affected by age: 93% in the YA group, 95% in the
adult group and 89% in the elderly group, P = 0.079 (Figure 3).
discussion
This study of 2784 Ph+ CML patients in early CP, enrolled in mul-
ticentric studies over a long period of time, shows that the clinical
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Figure 1. Overall survival (OS) by age groups (<30, 30–50, >60 years) in
the chemotherapy cohort (A), the rIFN-α cohort (B) and the TKIs cohort
(C). In the chemotherapy cohort, the 15-year survival was 20% [95% confi-
dence interval (CI) 12% to 28%] in young adults, 7% (95% CI 5% to 9%) in
adults and 2% (95% CI 0 to 4%) in the elderly (P < 0.001). In the rIFN-α
cohort, the 15-year survival was 39% in young adults (95% CI 25% to 53%),
22% in adults (95% CI 16% to 30%) and 10% (95% CI 3% to 24%) in the
elderly (P < 0.001). In the TKIs cohort, the 8-year survival was 93% (95% CI
80% to 98%) in young adults, 93% (95% CI 90% to 95%) in adults, and 77%
(95% CI 69% to 83%) in the elderly (P < 0.001). These survival calculations
were made counting all deaths, for any reason and without any censoring.
Table 4. TKIs cohort
Age group Patients,
N
Progressions,
N (%)
Deaths, N (%)
Leukemia-
related
Leukemia-
unrelated
Total
<30 years 56 8 (14) 3 (5) 0 3 (5)
30–59 years 457 21 (5) 18 (4) 8 (2) 26 (6)
>60 years 261 14 (5) 19a (7) 28 (11) 47 (18)
Total 774 43 (6) 40 (5) 36 (5) 76 (10)
Progression to AP and BP, as defined by ELN criteria (6), and death,
by age group. All leukemia-related deaths occurred after
transformation to AP or BP, with the exception of five elderly
patients who did not die in remission, but did not fit the criteria of
AP or BP.
aFive patients died because of leukemia without fitting the criteria of
AP and BP.
TKIs, tyrosine kinase inhibitors; AP, accelerated phase; BP, blastic
phase; ELN, European LeukemiaNet.
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Figure 2. Estimated cumulative probability of progression to AP and BP by
age groups (<30, 30–50, >60 years) in the TKIs cohort. At 8 years, it was
16% (95% CI 8% to 31%) in young adults, 5% (95% CI 3% to 8%) in adults
and 7% (95% CI 4% to 11%) in the elderly (P = 0.011).
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presentation of CML varies consistently and unidirectionally with
age, particularly because of differences in spleen enlargement,
leading to a relative excess of high-risk patients among YA. It was
already well known that the disease is more aggressive in children
[10–13]. A recent study on 150 patients younger than 18 years old
reported that the spleen was palpable in 78% of children, with a
median value of 8 cm below costal margin [13]. For children, a
high WBC, a high platelet count, and a high blast cell percentage
at the diagnosis have been reported [10–13]. Also a multicentric
study, including 120 patients 16–29 years old, reported that, in
adolescents and YA, the median value of spleen below costal
margin was 5versus 0 cm in the elderly group [14].
The splenomegaly is almost universally attributed to the ex-
pansion of myelopoiesis in the spleen. A classic textbook says:
‘In chronic phase the spleen is enlarged due to infiltration of the
red pulp cords by granulocytes in different maturation stages…’
[15]. Spleen is a hematopoietic organ in the fetus. In children,
adolescents and YA, the spleen niche may offer a more favorable
environment to Ph+ cells, than in older patients; alternatively, it
is possible that in younger patients Ph+ stem or progenitor cells
could be qualitatively different. There are few, not recent, studies
reporting on differences between marrow and spleen hemato-
poiesis in CML [16–18], but there are not studies investigating
the molecular profile of Ph+ cells in different age groups. The
spleen enlargement could be not only caused by myeloid meta-
plasia, but it could also be an expression of host reaction. In a
normal spleen, the lymphoid tissue account for about 65% of the
whole organ [15]. In CML patients, the exact proportion of
myeloid and lymphoid cells in the spleen is not known, apart
from an old report regarding 12 CML patients splenectomized at
the onset of the disease [16]: based on cytologic evaluation of
spleen touches (smears), the median lymphocyte proportion was
40% of all nucleated cells, suggesting that spleen enlargement was
due at least in part also to lymphocytes. This may represent an
inflammatory reaction, reflecting an age-related difference of the
immune-inflammatory response of the host.
The splenomegaly has been always recognized as a negative
prognostic factor [6–8, 15]. Also in our series of 2784 patients,
enrolled over a long period time, a multivariate analysis
confirmed that spleen size was a significant and independent
predictor of survival, regardless of age (data not shown). In the
pre-TKIs era, the great majority of deaths were preceded by
progression, so that they were attributed to leukemia. In the
TKIs era, the deaths not related to leukemia are also uncommon
in younger patients, but account for at least 50% of all deaths in
the elderly. The concept of leukemia-related survival raises
obvious difficulties, suspicions and resistances, because it
implies a shared definition, a detailed knowledge of the course
of the disease and of the death, and requires other specific bio-
statistical methods of analysis [19, 20]. However, in the current
TKIs era, the problem can no longer be ignored. It is not easy to
detect differences in response and outcome according to age,
since treatment is so effective and the number of YA patients is
small; 12% in our multicentric series of 2784 patients and 8%,
11%, 13% and 8%, respectively, in other reports, where adoles-
cents and YA were frequently grouped in the same age class [14,
21–23]. A difference in the probability of achieving a CCyR and
an MMR, according to age, was found in our series and in an in-
dependent single-center study [23], but not in another multi-
centric study on patients from 16 to 29 years old [14]. In all the
studies, the OS and the progression-free survival were not
affected by age. The more aggressive disease characteristics in
YA may explain the lower response rates and the relatively
higher probability early disease progression. The impact of a
poorer adherence, if any, should be clarified.
In conclusion, we extended to YA the observations already
made in children. The most relevant difference was in the spleen
size, and a continuous decrease of spleen size by age has been
observed. It is acknowledged that the age is a continuous vari-
able, and that cutoffs are artificial. Moreover, selection biases
could not be excluded, because patients enrolled in clinical trials
may not reflect the characteristics of the whole CML population.
We repeated all the calculations reported in this paper, also con-
sidering different cutoffs, particularly 18–39, 40–59, 60–69 and
≥70 years old: the results did not change. In the current TKI
era, multiple treatment choices are available, the differences are
small, and the treatment goals may be different according to the
age of CML patients [5, 24]. Our data suggest that investigating
the differences according to age may be important for under-
standing the biology of the disease and the response of the host,
in order to design age-adapted strategies. A careful monitoring
of YA patients should be carried out. It is likely that in YA
an extended use of second-generation TKIs may improve the
outcome.
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